Physician profile
Scott Boyens
NPI 1700886389
$6,200.59
in general payments reported to CMS, 2019-2025
43 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $830 · 2021: $515 · 2022: $848 · 2023: $1,379 · 2024: $898 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,333.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $613.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $606.69 | 2019-2025 | |
| Abbvie INC. | $577.34 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Dexcom, INC. | $499.50 | 2019-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $486.85 | 2019-2025 | Evenity, Prolia |
| Lilly USA, LLC | $478.20 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $472.34 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $258.37 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.02 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $183.89 | 2022-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $178.89 | 2020-2022 | |
| Exact Sciences Corporation | $153.09 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $152.49 | 2019-2020 | |
| Daiichi Sankyo INC. | $134.92 | 2022-2023 | Injectafer |
| Glaxosmithkline, LLC. | $113.10 | 2021-2023 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Boyens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.